Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study.

IF 1.6 4区医学 Q4 ONCOLOGY

Anticancer research Pub Date : 2025-03-01 DOI:10.21873/anticanres.17505

Leticia Iglesias, Rocío Vílchez, Santiago Aguín, Ramón García, Carolina Pena, Alberto Carral, Gerardo Huidobro, Aurea Molina, Jesús García Gómez, Marta Covela, Marinha Costa, Ana Medina

{"title":"Real-world Outcomes in Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck With Nivolumab: Galician Study.","authors":"Leticia Iglesias, Rocío Vílchez, Santiago Aguín, Ramón García, Carolina Pena, Alberto Carral, Gerardo Huidobro, Aurea Molina, Jesús García Gómez, Marta Covela, Marinha Costa, Ana Medina","doi":"10.21873/anticanres.17505","DOIUrl":null,"url":null,"abstract":"Background/aim: Real-world evidence regarding the use of nivolumab in metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is limited. This study aimed to describe the clinical characteristics, outcomes, and safety of nivolumab in R/M SCCHN patients treated in routine clinical practice.Patients and methods: This retrospective, observational study evaluated the efficacy/safety of nivolumab in 116 patients with R/M SCCHN treated at nine centers within the Galician Group of Head and Neck Cancer health network between 2017 and 2019.Results: Basal characteristics of patients included a median age of 60 years, ECOG performance status -2 (14%) and -3 (1%) and a first diagnosis of stage IV a/b/c (74%). Nivolumab was used as first line, second line, and third line therapy in 17%, 66%, and 17% of patients, respectively. After a median follow-up of 14 months (range=1-69 months), the median progression-free survival was 2.30 months (95%CI=1.45-3.14) and the median overall survival was 8.1 months (95%CI=5.93-10.23). Outcomes were better when nivolumab was administered earlier in treatment course. Grade 3/4 adverse events were observed in 21.27% of patients.Conclusion: These findings support the efficacy and safety of nivolumab in the real-world treatment of R/M SCCHN.","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 3","pages":"1181-1191"},"PeriodicalIF":1.6000,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17505","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Real-world evidence regarding the use of nivolumab in metastatic squamous cell carcinoma of head and neck (R/M SCCHN) is limited. This study aimed to describe the clinical characteristics, outcomes, and safety of nivolumab in R/M SCCHN patients treated in routine clinical practice.

Patients and methods: This retrospective, observational study evaluated the efficacy/safety of nivolumab in 116 patients with R/M SCCHN treated at nine centers within the Galician Group of Head and Neck Cancer health network between 2017 and 2019.

Results: Basal characteristics of patients included a median age of 60 years, ECOG performance status -2 (14%) and -3 (1%) and a first diagnosis of stage IV a/b/c (74%). Nivolumab was used as first line, second line, and third line therapy in 17%, 66%, and 17% of patients, respectively. After a median follow-up of 14 months (range=1-69 months), the median progression-free survival was 2.30 months (95%CI=1.45-3.14) and the median overall survival was 8.1 months (95%CI=5.93-10.23). Outcomes were better when nivolumab was administered earlier in treatment course. Grade 3/4 adverse events were observed in 21.27% of patients.

Conclusion: These findings support the efficacy and safety of nivolumab in the real-world treatment of R/M SCCHN.

查看原文本刊更多论文

尼武单抗治疗头颈部复发/转移性鳞状细胞癌的实际疗效：加利西亚研究

背景/目的：关于使用纳武单抗治疗头颈部转移性鳞状细胞癌（R/M SCCHN）的实际证据有限。本研究旨在描述nivolumab在常规临床实践中治疗的R/M SCCHN患者的临床特征、结局和安全性。患者和方法：这项回顾性观察性研究评估了2017年至2019年在加利西亚头颈癌健康网络内的9个中心治疗的116例R/M SCCHN患者的nivolumab的疗效/安全性。结果：患者的基本特征包括中位年龄60岁，ECOG表现状态为-2（14%）和-3(1%)，首次诊断为IV期a/b/c（74%）。Nivolumab分别用于17%、66%和17%的患者的一线、二线和三线治疗。中位随访14个月（范围1-69个月）后，中位无进展生存期为2.30个月（95%CI=1.45-3.14），中位总生存期为8.1个月（95%CI=5.93-10.23）。在疗程早期给予纳武单抗治疗效果更好。21.27%的患者出现3/4级不良事件。结论：这些发现支持纳武单抗在现实世界中治疗R/M SCCHN的有效性和安全性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Anticancer research 医学-肿瘤学

CiteScore

3.70

自引率

10.00%

发文量

566

审稿时长

2 months

期刊介绍： ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed. ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies). Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.